Therefore, the question of whether surgical treatment of the primary breast lesion in HER2-positive patients with de novo advanced breast cancer would provide additional benefits to this subset of patients is commonly encountered in clinical practice. This evidence concerns the gene ERBB2 and breast carcinoma.